Bristol-Myers Squibb Revenue 2006-2018 | BMY

Bristol-Myers Squibb annual/quarterly revenue history and growth rate from 2006 to 2018. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Bristol-Myers Squibb revenue for the quarter ending June 30, 2018 was $5.704B, a 10.89% increase year-over-year.
  • Bristol-Myers Squibb revenue for the twelve months ending June 30, 2018 was $21.600B, a 6.73% increase year-over-year.
  • Bristol-Myers Squibb annual revenue for 2017 was $20.776B, a 6.94% increase from 2016.
  • Bristol-Myers Squibb annual revenue for 2016 was $19.427B, a 17.31% increase from 2015.
  • Bristol-Myers Squibb annual revenue for 2015 was $16.56B, a 4.29% increase from 2014.
Bristol-Myers Squibb Annual Revenue
(Millions of US $)
2017 $20,776
2016 $19,427
2015 $16,560
2014 $15,879
2013 $16,385
2012 $17,621
2011 $21,244
2010 $19,484
2009 $18,808
2008 $17,715
2007 $15,617
2006 $16,208
2005 $18,605
Bristol-Myers Squibb Quarterly Revenue
(Millions of US $)
Q2 2018 $5,704
Q1 2018 $5,193
Q4 2017 $5,449
Q3 2017 $5,254
Q2 2017 $5,144
Q1 2017 $4,929
Q4 2016 $5,243
Q3 2016 $4,922
Q2 2016 $4,871
Q1 2016 $4,391
Q4 2015 $4,287
Q3 2015 $4,069
Q2 2015 $4,163
Q1 2015 $4,041
Q4 2014 $4,258
Q3 2014 $3,921
Q2 2014 $3,889
Q1 2014 $3,811
Q4 2013 $4,441
Q3 2013 $4,065
Q2 2013 $4,048
Q1 2013 $3,831
Q4 2012 $4,191
Q3 2012 $3,736
Q2 2012 $4,443
Q1 2012 $5,251
Q4 2011 $5,454
Q3 2011 $5,345
Q2 2011 $5,434
Q1 2011 $5,011
Q4 2010 $5,111
Q3 2010 $4,798
Q2 2010 $4,768
Q1 2010 $4,807
Q4 2009 $5,033
Q3 2009 $4,788
Q2 2009 $4,665
Q1 2009 $4,322
Q4 2008 $2,367
Q3 2008 $5,254
Q2 2008 $5,203
Q1 2008 $4,891
Q4 2007 $2,228
Q3 2007 $4,601
Q2 2007 $4,471
Q1 2007 $4,317
Q4 2006 $2,507
Q3 2006 $4,154
Q2 2006 $4,871
Q1 2006 $4,676
Q4 2005 $4,417
Q3 2005 $4,767
Q2 2005 $4,889
Q1 2005 $4,532
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $94.166B $20.776B
Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious and life-threatening diseases. Their employees around the world work together for patients - it drives everything they do. They are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience and fibrosis. Through their R&D organization, they have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate their work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $359.375B 17.17
Pfizer (PFE) United States $256.688B 15.02
Novartis AG (NVS) Switzerland $192.696B 16.53
Merck (MRK) United States $187.277B 16.54
AbbVie (ABBV) United States $135.043B 13.19
Eli Lilly (LLY) United States $118.805B 21.99
Sanofi (SNY) France $108.926B 13.79
Novo Nordisk (NVO) Denmark $103.361B 16.52
GlaxoSmithKline (GSK) United Kingdom $96.420B 12.87
AstraZeneca (AZN) United Kingdom $94.908B 10.44